Does Gammora Really Kills 99% Of HIV/Aids Virus?

A new drug from Zion Medical named—Gammora claims to kill 99 % of the HIV virus during the first human trial.

The therapy was made to kill HIV-infected cells without damaging uninfected ones.

Compared to current antiretroviral medications that only suppress the spread of this virus, Gammora provides hope that a real cure may one day be discovered.

According to the company, The drug was proven to eliminate around 99 % of HIV in four months of therapy.

Gammora is a complex remedy composed of a synthetic peptide compound derived from the HIV-derived integrase.

Taking advantage of the procedure, Gammora arouses the integration of numerous HIV DNA fragments to the host cell’s genomic DNA.

But the question is, does it really kill 99% of HIV? First, let’s find out how does it work?

How does Gammora work?

Zion Medical describes the mode of activity as follows.

Gammora is a synthetic peptide compound derived from the HIV enzyme integrase, responsible for integrating the virus’s genetic material into the infected cell’s DNA. Gammora arouses the integration of multiple HIV DNA fragments to the host cell’s genomic DNA, which activates the self-destruction of the infected cell, known as apoptosis.

The drug seems to be a broad-spectrum disrupter of viral replication (such as ribavirin, a drug previously utilized in hepatitis C therapy ). It may restrict viral proliferation in established diseases and the disease of cells that are further (as other antiretroviral medications do).

“These initial clinical outcomes were beyond our expectations and assure confidence in finding a cure for a disease that has been detected within 35 years,” said in a statement Dr. Esmira Naftali, head of growth in Zion Medical. “Given the restricted nature of the study, we’re eager to show the efficacy of our medication in Phase 2b using a larger number of participants within a longer period.”

If this stage proves equally effective, its consequences will be life-altering. Now, present commercially available HIV retroviral treatments work by curbing the spread of this virus but don’t provide any treatment for the disease.

Therefore, HIV patients may only hope for a better lifespan, not an actual respite. Nevertheless, Zion Medical’s peptide can destroy all cells carrying the HIV virus genome, offering a true cure for contaminated patients.

Zion Medical’s Stage 1/2a Gammora human clinical trial found that many patients revealed a substantial decrease in the viral burden of around 90 percent in the baseline through the initial four months.

In Part II of this analysis, Gammora was further combined with added retroviral remedies, resulting in patients showing around a 99 percent decrease in viral load from baseline in four months.

Additionally, during the whole process of evaluations, Gammora has been proven to be secure and well-tolerable. In reality, no side effects at all have been reported.

What’s more, Gammora was discovered to boost individual CD4 cell count — around 97 percent in the baseline. CD4 cells also called some T cells or T cells, are the cells that HIV kills. They’re white blood cells that play an integral part in the human immune system, the body’s natural defense mechanisms against germs, diseases, and disorders.

“Zion Medical’s Gammora is a synthetic peptide compound derived from the HIV enzyme integrase, which helps insert genetic material into cells. This process stimulates apoptosis in infected tissues and triggers their self-destruction.”

The drug appears to have anti-viral properties. It might work by limiting the amount of virus in an existing infection and preventing it from spreading further (like other antiretrovirals). However, no evidence suggests this particular medication can clear out latently infected cells that already contain integrated HIV DNA; if we were curing patients, they would need something entirely different for their treatment plan since all current drugs target actively recruiting cell surfaces.

Since HIV infections advancement, CD4 cells have considerably decreased. Someone will be diagnosed with AIDS if their numbers fall below 200 and subsequently be considered at high risk of developing serious illnesses. A healthy person’s typical range for CD4 cells is roughly 500-1,500.

The favorable news caused quite a few frenzies directing Zion Medical to describe the company still has a long way before a remedy could be ensured, but it has gotten a measure nearer. The business also disclosed that its peer-reviewed research ought to be accessible in 2019.

An Israeli-based pharmaceutical firm, Zion Medical, which recently broke the news of an adequate initial clinical trial because of what they predicted as a possible HIV remedy, has issued a further statement on Twitter which makes it crystal clear that more trials will be required, and also their official outcomes need to get peer-reviewed and published.

Since the organization was announced on 31 October, there’s been a tide of enthusiasm on social websites, particularly with people clamoring to learn more about this”possible cure.”

Zion Medical is a relatively new firm based in 2014. According to the business site, it manufactures AIDS and Cancer treating products on peptides derived from HIV and targeted lentivirus (LV) particles.

The FDA has recently approved Dovato— a combination of two antiretroviral drugs like dolutegravir and lamivudine for the treatment of HIV.

You can also read more information related to medicine and supplements on DrugsBank.

Read more trending topics.

• Focus Factor Review: Does It Works?
• Zyrexin Review: Uses, Dosage, Side Effects, Customer Reviews
• 15 Best Vein Finders Available On The Market
• Tebo Massage Chair: Everything From A-Z